Dr. Jackie Hunter

BenevolentAI

AI accelerates drug discovery and development through data mining

Dr. Jackie Hunter, board member of BenevolentAI, discusses its project that targets glioblastoma and how BenevolentAI has used its technology to come up with new hypotheses for therapeutic agents. This video explains why artificial intelligence (AI) will be transformational for drug discovery and drug development and how it can enhance diagnosis to rapidly detect disease such as cancer.



LIKE 3
Dr. Jackie Hunter
SLAS2020

Dr. Jackie Hunter

Biography

Dr. Jackie Hunter gained her... More
Follow Jackie

Dr. Jackie Hunter

BenevolentAI

Dr. Jackie Hunter gained her Ph.D. in psychology in 1980 from Royal Holloway, University of London. After gaining her Ph.D., she became Senior Vice President and Head of the Neurology and GI Centre of Excellence for Drug Discovery (CEDD) at GlaxoSmithKline (GSK). Following this, she became CEO of BenevolentBio and is now the Board Director of BenevolentAI.